Encouraging SNT-4728 Phase 2 iRBD results
Filed with ASX · · 5 pages · English
In the deck
Earlier from Syntara
- Results of Share Purchase Plan
- Share Purchase Plan Offer Booklet
- $8m placement and share purchase plan
- Continuation of trading halt
- Positive FDA feedback for Amsulostat P2b trial
Later from Syntara
- Appendix 4E and Annual Report
- Syntara expands SNT-9465 skin scarring study
- Further significant results from SNT-4728 iRBD Phase 2 trial
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara